Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and ADME of Savolitinib in Healthy Males
NCT04675021Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of savolitinib in cancer, sponsored by AstraZeneca. Primary endpoints: Absolute Bioavailability (F) of savolitinib, Cumulative amount of AZD6094 (savolitinib) excreted (CumAe) and 2 more. Started Nov 2020; status: completed.
02
Drugs
savolitinib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04675021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675021.